Rafferty Asset Management
FATE icon

Rafferty Asset Management’s Fate Therapeutics FATE Stock Holding History

Rafferty Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-214,425
Closed -$750K – 1153
2024
Q3 		$750K Sell
214,425
-36,368
-15% -$142K ﹤0.01% 859
2024
Q2 		$823K Sell
250,793
-478,864
-66% -$2.1M ﹤0.01% 857
2024
Q1 		$5.36M Buy
+729,657
New +$4.52M 0.02% 462
2023
Q3 		– Sell
-955,120
Closed -$4.55M – 1084
2023
Q2 		$4.55M Sell
955,120
-438,845
-31% -$2.42M 0.03% 437
2023
Q1 		$7.95M Buy
1,393,965
+967,382
+227% +$5.84M 0.05% 247
2022
Q4 		$4.3M Buy
426,583
+180,108
+73% +$3.38M 0.04% 410
2022
Q3 		$5.52M Buy
246,475
+53,651
+28% +$1.55M 0.06% 321
2022
Q2 		$4.78M Buy
192,824
+33,434
+21% +$922K 0.04% 283
2022
Q1 		$6.18M Buy
159,390
+52,122
+49% +$2.02M 0.04% 321
2021
Q4 		$6.28M Buy
107,268
+61,723
+136% +$3.5M 0.03% 287
2021
Q3 		$2.7M Buy
45,545
+16,478
+57% +$1.29M 0.02% 538
2021
Q2 		$2.52M Sell
29,067
-55,708
-66% -$4.49M 0.02% 595
2021
Q1 		$6.99M Buy
84,775
+67,811
+400% +$6.5M 0.05% 224
2020
Q4 		$1.54M Sell
16,964
-42,159
-71% -$2.62M 0.02% 439
2020
Q3 		$2.36M Buy
59,123
+28,058
+90% +$980K 0.03% 367
2020
Q2 		$1.07M Buy
+31,065
New +$926K 0.02% 525
2020
Q1 		– Sell
-60,015
Closed -$1.17M – 678
2019
Q4 		$1.17M Sell
60,015
-95,601
-61% -$1.52M 0.02% 514
2019
Q3 		$2.42M Buy
155,616
+49,267
+46% +$944K 0.04% 294
2019
Q2 		$2.16M Sell
106,349
-51
-0% -$919 0.04% 401
2019
Q1 		$1.87M Buy
+106,400
New +$1.68M 0.03% 420

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Rafferty Asset Management's FATE Position: Q4 2024 in Review

Rafferty Asset Management sold out of Fate Therapeutics (FATE) in Q4 2024, closing a stake of 214,425 shares — an estimated $750K sold.

Rafferty Asset Management first reported a position in FATE in Q1 2019 and held it in 20 quarters. The position peaked at $7.95M in Q1 2023. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2024.

  • Rafferty Asset Management reported no remaining Fate Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Rafferty Asset Management sold 214,425 Fate Therapeutics shares in Q4 2024, an estimated $750K.
  • Rafferty Asset Management first reported a position in Fate Therapeutics in Q1 2019 and held it in 20 quarters.
  • Rafferty Asset Management's Fate Therapeutics position peaked at $7.95M in Q1 2023.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2024.

Based on Rafferty Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.